同时放化疗联合康莱特注射液治疗Ⅲ期非小细胞肺癌

The efficacy of concurrent chemotherapy and radiotherapy combined with Kanglaite injectim in the treatment on non-small cell lang cancer patients.

目的观察康莱特注射液在同时放化疗治疗非小细胞肺癌中的作用.方法采用随机分组将68例患者分为康莱特加放化疗组(观察组)和不加康莱特组(对照组),化疗采用EP方案,足叶乙甙100mg/d,连用5天,顺铂20mg/㎡/d,连用4～5天;放疗采用常规放疗,Dt60～66Gy/30～36次/6～8周;康莱特注射液,100ml-200ml/d,连用20天以上.通过CT及胸部X线正侧位片观察放疗前中后肿瘤消退情况,通过KPS评分、体重变化观察生活质量改善情况,通过血常规、肝肾功能、免疫功能测定观测联合治疗的毒性反应情况.结果观察组和对照组完全缓解率及有效率分别为61.8%、35.3%和88.2%、76.4%,观察组与对照组相比,明显改善了生活质量,提高了患者免疫功能,在一定程度上减轻了血液学毒性反应.结论康莱特在肿瘤放化疗中能改善患者的生活质量,提高患者免疫功能,并有可能进一步提高非小细胞肺癌同时放化疗的疗效.

Objectire To analyze Kanglaite’s action in concurrent chemotherapy and radiotherapy for NSCLC. Methods sixty eight patients with stage Ⅲ NSCLC were randomized to two groups, Kanglaite group (Kanglaite+ chemoradiation) and control group (concurrent chemoradiation). The chemotherapy plan was EP, (Etoposid, 100mg/d, continuous 5 days, Cisplatin 30mg//d, continuous 4～5 days). The radiotherapy plan was conventional radiotherapy, Dt60-66Gy/30-36times/6～8weeks. Kanglaite was given in 100-200ml/d, continuous more than 20 days.Results The CR and PR in Kanglaite group and non- Kanglaite group were 61.8%, 35.3% (P<0.05) and 88.2%, 76.4%, respectively. There were obvious differences in the improvement of life quality and immunologic function and there was not serious blood poisonous reaction in two groups. Conclusion Kanglaite may promote the therapeutic effect of NSCLC concurrent chemoradiation by improving the life quality and immunologic function of NSCLC patients.